Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago
🌐 বাংলায় দেখুন

Indications

Chronic Obstructive Pulmonary Disease Bronchitis Sinusitis Pharyngitis Tonsillitis Bacterial Infection Respiratory Tract Infection Otitis Media

It is indicated for treating infections caused by sensitive bacteria. This includes pharyngitis and tonsillitis caused by Streptococcus pyogenes; acute bacterial otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (including beta-lactamase producing strains) or Streptococcus pyogenes; acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non beta-lactamase producing strains); lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains), Klebsiella species, Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes or E. coli; acute bacterial exacerbation of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains) or Haemophilus parainfluenzae (beta-lactamase negative strains); skin and skin structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) or Streptococcus pyogenes; urinary tract infections caused by E. coli or Klebsiella pneumoniae; bone and joint infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains); gonorrhoea caused by penicillinase-producing and non-penicillinase-producing strains of Neisseria gonorrhoeae; and early Lyme disease (erythema migrans) caused by Borrelia burgdorferi.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Cefuroxime is a well-studied, effective antibacterial with broad-spectrum bactericidal activity against a wide range of common pathogens, including strains that produce β-lactamase. Because it resists breakdown by bacterial β-lactamase, it remains active against many strains that are resistant to ampicillin and amoxycillin.

Pregnancy & Breastfeeding

Cefuroxime falls under US FDA pregnancy category B. That said, well-controlled studies in pregnant women are lacking, and since animal studies don't always predict how humans will respond, this medicine should only be used in pregnancy when clearly necessary. Cefuroxime does pass into breast milk, so it should be used with caution in nursing mothers.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Dosage Tablet or Suspension. Adolescents and adults (13 years and older): for pharyngitis or tonsillitis, 250 mg twice daily for 5 to 10 days. Acute bacterial maxillary sinusitis: 250 mg twice daily for 10 days. Acute bacterial exacerbation of chronic bronchitis: 250 to 500 mg twice daily for 10 days. Secondary bacterial infections of acute bronchitis: 250 to 500 mg twice daily for 5 to 10 days. Uncomplicated skin and skin structure infections: 250 to 500 mg twice daily for 10 days. Uncomplicated urinary tract infections: 250 mg twice daily for 7 to 10 days. Uncomplicated gonorrhoea: 1000 mg as a single dose. Community acquired pneumonia: 250 to 500 mg twice daily for 5 to 10 days. MDR typhoid fever: 500 mg twice daily for 10 to 14 days. Early Lyme disease: 500 mg twice daily for 20 days. Paediatric patients (3 months to 12 years): for pharyngitis or tonsillitis, 20 mg/kg/day in two divided doses for 5 to 10 days. Acute otitis media: 30 mg/kg/day in two divided doses for 10 days. Acute bacterial maxillary sinusitis: 30 mg/kg/day in two divided doses for 10 days. Impetigo: 30 mg/kg/day in two divided doses for 10 days. Parenteral. Adult: 750 mg three times daily by IM or IV injection. In severe infections, the dose can be increased up to 1.5 gm three times daily by IV injection. The frequency may be increased to four times daily if necessary, giving total daily doses of 3 to 6 gms. Children above 3 months of age: 30 to 100 mg/kg/day given in 3 or 4 equally divided doses. A dose of 60 mg/kg/day is appropriate for most infections. Neonate: 30 to 100 mg/kg/day given in 2 or 3 equally divided doses. Surgical prophylaxis: 1.5 gm by IV injection at induction of anaesthesia, with up to 3 further doses of 750 mg given by IV or IM injection every 8 hours for high risk procedures. Pneumonia: 1.5 gm by IV injection twice daily for 2 to 3 days, followed by 500 mg twice daily by mouth for 7 to 10 days. Acute exacerbations of chronic bronchitis: 750 mg twice daily by IM or IV injection for 2 to 3 days, followed by 500 mg twice daily by mouth for 5 to 10 days. The duration of both parenteral and oral therapy is determined by the severity of the infection and the clinical status of the patient. In gonorrhoea, adults are given 1.5 gm as a single dose, as two 750 mg injections given intramuscularly at different sites, such as each buttock. In meningitis, adults are given 3 gm by IV injection three times daily. Children above 3 months of age: 200 to 240 mg/kg/day by IV injection in 3 or 4 divided doses, reduced to 100 mg/kg/day after 3 days or on clinical improvement. Neonate: an initial dose of 100 mg/kg/day by IV injection, reduced to 50 mg/kg/day when clinically indicated. In bone and joint infections, adults are given 1.5 gm by IV injection four times daily. Children above 3 months of age: 150 mg/kg/day, not to exceed the maximum adult dose, in equally divided doses every 8 hours.